{"id":"minodronic-acid-hydrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Jaw osteonecrosis (ONJ)"},{"rate":null,"effect":"Atypical fractures"}]},"_chembl":{"chemblId":"CHEMBL319144","moleculeType":"Small molecule","molecularWeight":"322.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a nitrogen-containing bisphosphonate, minodronic acid accumulates in bone and is taken up by osteoclasts during bone resorption. It inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases essential for osteoclast function and survival, thereby reducing bone turnover and increasing bone mineral density.","oneSentence":"Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:29.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone loss associated with cancer treatment"}]},"trialDetails":[{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":"Postmenopausal Osteoporosis","enrollment":72},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":"Osteoporosis","enrollment":330},{"nctId":"NCT02166437","phase":"","title":"Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese","status":"UNKNOWN","sponsor":"Tomidahama Hospital","startDate":"2013-11","conditions":"Osteoporosis","enrollment":500},{"nctId":"NCT00212628","phase":"PHASE3","title":"Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2004-06","conditions":"Involutional Osteoporosis","enrollment":444}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DECREASED APPETITE"},{"count":3,"reaction":"FALL"},{"count":2,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":2,"reaction":"AMAUROSIS FUGAX"},{"count":2,"reaction":"GASTRITIS"},{"count":2,"reaction":"LOSS OF CONSCIOUSNESS"},{"count":2,"reaction":"MELAENA"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PLATELET COUNT DECREASED"},{"count":2,"reaction":"PNEUMONIA"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Minodronic acid hydrate","genericName":"Minodronic acid hydrate","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minodronic acid hydrate is used to treat conditions such as osteoporosis, involutional osteoporosis, and postmenopausal osteoporosis. It is a medication that has been studied in clinical trials, including a Phase III trial for postmenopausal women with osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}